Israel - Tiếng Anh - Ministry of Health

novo nordisk ltd., israel - eptacog alfa (activated) - powder for solution for injection - eptacog alfa (activated) 5 mg/vial - eptacog alfa (activated) - eptacog alfa (activated) - novoseven ® rt is indicated for the treatment of bleeding episodes and for the prevention of bleeding in those undergoing surgery or invasive procedures in the following patient groups: •in patients with congenital haemophilia with inhibitors to coagulation factors viii or ix > 5 bethesda units (bu) •in patients with congenital haemophilia who are expected to have a high anamnestic response to factor viii or factor ix administration •in patients with acquired haemophilia •in patients with congenital fvii deficiency •in patients with glanzmann’s thrombasthenia with past or present refractoriness to platelet transfusions, or where platelets are not readily available.severe postpartum haemorrhagenovoseven rt is indicated for the treatment of severe postpartum haemorrhage when uterotonics are insufficient to achieve haemostasis

Malaysia - Tiếng Anh - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

novo nordisk pharma (malaysia) sdn. bhd. - insulin aspart -

New Zealand - Tiếng Anh - Medsafe (Medicines Safety Authority)

novo nordisk pharmaceuticals ltd - insulin detemir 100 u/ml - solution for injection - 100 u/ml - active: insulin detemir 100 u/ml excipient: dibasic sodium phosphate dihydrate glycerol hydrochloric acid metacresol phenol sodium chloride sodium hydroxide water for injection zinc - for the treatment of diabetes mellitus

New Zealand - Tiếng Anh - Medsafe (Medicines Safety Authority)

novo nordisk pharmaceuticals ltd - neutral insulin, human, pyr 100 iu/ml;   - solution for injection - 100 iu/ml - active: neutral insulin, human, pyr 100 iu/ml   excipient: glycerol hydrochloric acid metacresol sodium hydroxide water for injection zinc - treatment of diabetes mellitus. furthermore indicated for the initial stabilisation of diabetes, during treatment of diabetic ketoacidosis and the hyperosmolar non ketotic syndrome, and during stress situations such as severe infections and major surgery in diabetic patients.

New Zealand - Tiếng Anh - Medsafe (Medicines Safety Authority)

novo nordisk pharmaceuticals ltd - isophane insulin, human, pyr 70 iu/ml;  ; neutral insulin, human, pyr 30 iu/ml;   - suspension for injection - active: isophane insulin, human, pyr 70 iu/ml   neutral insulin, human, pyr 30 iu/ml   excipient: dibasic sodium phosphate dihydrate glycerol hydrochloric acid metacresol phenol protamine sulfate sodium hydroxide water for injection zinc as chloride, approx - treatment of diabetes mellitus.

New Zealand - Tiếng Anh - Medsafe (Medicines Safety Authority)

novo nordisk pharmaceuticals ltd - isophane insulin, human, pyr 60 iu/ml;  ; neutral insulin, human, pyr 40 iu/ml;   - suspension for injection - active: isophane insulin, human, pyr 60 iu/ml   neutral insulin, human, pyr 40 iu/ml   excipient: dibasic sodium phosphate dihydrate glycerol hydrochloric acid metacresol phenol protamine sulfate sodium hydroxide water for injection zinc as chloride, approx. - treatment of diabetes mellitus.

New Zealand - Tiếng Anh - Medsafe (Medicines Safety Authority)

novo nordisk pharmaceuticals ltd - isophane insulin, human, pyr 50 iu/ml;  ; neutral insulin, human, pyr 50 iu/ml;   - suspension for injection - active: isophane insulin, human, pyr 50 iu/ml   neutral insulin, human, pyr 50 iu/ml   excipient: dibasic sodium phosphate dihydrate glycerol hydrochloric acid metacresol phenol protamine sulfate sodium hydroxide water for injection zinc as chloride, approx. - treatment of diabetes mellitus.

New Zealand - Tiếng Anh - Medsafe (Medicines Safety Authority)

novo nordisk pharmaceuticals ltd - isophane insulin, human, pyr 100 iu/ml;   - suspension for injection - 100 iu/ml - active: isophane insulin, human, pyr 100 iu/ml   excipient: dibasic sodium phosphate dihydrate glycerol hydrochloric acid metacresol phenol protamine sulfate sodium hydroxide water for injection zinc - treatment of diabetes mellitus.

New Zealand - Tiếng Anh - Medsafe (Medicines Safety Authority)

novo nordisk pharmaceuticals ltd - neutral insulin, human, pyr 100 iu/ml;   - solution for injection - 100 iu/ml - active: neutral insulin, human, pyr 100 iu/ml   excipient: glycerol hydrochloric acid metacresol sodium hydroxide water for injection zinc - treatment of diabetes mellitus. furthermore indicated for the initial stabilisation of diabetes, during treatment of diabetic ketoacidosis and the hyperosmolar non ketotic syndrome, and during stress situations such as severe infections and major surgery in diabetic patients.

New Zealand - Tiếng Anh - Medsafe (Medicines Safety Authority)

novo nordisk pharmaceuticals ltd - glucagon hydrochloride 1mg (recombinant);  ;   - solution for injection - 1 mg - active: glucagon hydrochloride 1mg (recombinant)     excipient: lactose monohydrate water for injection - therapeutic treatment of severe hypoglycaemic reactions, which may occur in the management of diabetic patients receiving insulin or oral hypoglycaemic agents. to prevent the occurrence of secondary hypoglycaemia, oral carbohydrate should be given to restore the hepatic glycogen when the patient has responded to the treatment. the mechanism and hence treatment of sulfonylurea-induced hypoglycaemia differs from that of severe insulin-induced hypoglycaemia in some important ways. consciousness should preferably be restored by the administration of intravenous glucose. if glucagon is used due to the unavailability of intravenous glucose (e.g. before reaching a hospital) care should be taken to protect against secondary hypoglycaemia with constant monitoring of the patient's blood sugar level by medical personnel. subsequent administration of intravenous glucose may be required.